Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Jazz Pharmaceuticals PLC (JAZZ)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Jazz Pharma's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
107.43 -0.89    -0.82%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
109.51
+2.08
+1.94%
19:57:25 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 419,414
  • Bid/Ask: 109.50 / 117.99
  • Day's Range: 107.22 - 109.05
Jazz Pharma 107.43 -0.89 -0.82%

JAZZ Recent Sentiments

 
This page contains information on users’ sentiments for the Jazz Pharmaceuticals PLC stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Apr 22, 2024 Adem Sahin   108.52 +1.00%
Apr 16, 2024 Andres Herrera   109.11 Apr 22, 2024 @ 109.68 +0.52%
Apr 12, 2024 Andres Herrera   110.56 Apr 15, 2024 @ 111.53 +0.88%
Apr 10, 2024 Naji Bourgeily   113.05 Apr 15, 2024 @ 111.53 -1.34%
Mar 06, 2024 ניר ביתן   117.54 Mar 29, 2024 @ 120.42 +2.45%
Feb 29, 2024 João Santos   118.66 Mar 22, 2024 @ 121.81 +2.65%
Feb 28, 2024 Oceane Seel   131.03 Mar 22, 2024 @ 121.81 -7.04%
Feb 27, 2024 Juan Gomez   132.77 Mar 04, 2024 @ 117.81 -11.27%
Feb 14, 2024 Frank Luzar   122.01 Mar 08, 2024 @ 117.53 -3.67%
Jan 19, 2024 Aryaan Talwar   115.41 Feb 09, 2024 @ 123.43 -6.95%
Jan 09, 2024 Josep Navarro   122.38 Feb 02, 2024 @ 122.90 +0.42%
Jan 08, 2024 Adem Sahin   125.18 Feb 02, 2024 @ 122.90 -1.82%
Jan 02, 2024 Boris Ivanov   123.00 Jan 08, 2024 @ 124.47 +1.20%
Dec 06, 2023 job job   121.47 Dec 06, 2023 @ 121.65 +0.15%
Dec 04, 2023 Adem Sahin   120.78 Dec 29, 2023 @ 123.00 +1.84%
Nov 28, 2023 Aleksejs Volgins   115.93 Dec 22, 2023 @ 121.25 +4.59%
Nov 17, 2023 Gil Santos   121.14 Dec 08, 2023 @ 120.42 +0.59%
Nov 09, 2023 Juan Gomez   128.00 Nov 30, 2023 @ 114.26 -10.73%
Oct 20, 2023 Alejandro Garcia   136.00 Nov 30, 2023 @ 114.26 -15.99%
Oct 17, 2023 Josep Sanchez reina   134.82 Nov 30, 2023 @ 114.26 -15.25%
Oct 05, 2023 Yamina Alfaro   127.25 Nov 30, 2023 @ 114.26 -10.21%
Sep 06, 2023 Adem Sahin   138.79 Nov 30, 2023 @ 114.26 -17.67%
Aug 18, 2023 Curzio Cavallarin   138.62 Nov 30, 2023 @ 114.26 -17.57%
Jul 21, 2023 Marco Zanetti   130.71 Jul 27, 2023 @ 131.00 +0.22%
Jul 19, 2023 Gabriele Capaccioli   131.75 Nov 30, 2023 @ 114.26 -13.28%
Jul 19, 2023 Liam Stewart   131.04 Nov 30, 2023 @ 114.26 -12.81%
Jun 15, 2023 Massimo Vaghi   128.96 Nov 30, 2023 @ 114.26 -11.40%
Jun 12, 2023 Diego Medina Garcia   127.09 Nov 30, 2023 @ 114.26 -10.10%
Jun 05, 2023 Josep Navarro   127.15 Nov 30, 2023 @ 114.26 -10.14%
Apr 24, 2023 Miki Tashima   143.78 Apr 26, 2023 @ 141.18 -1.81%
Mar 24, 2023 Josep Navarro   140.68 Apr 14, 2023 @ 145.52 +3.44%
Mar 01, 2023 oscar fernando...   140.74 Mar 24, 2023 @ 141.28 +0.38%
Feb 13, 2023 Josep Navarro   150.28 Mar 10, 2023 @ 134.06 -10.79%
Jan 03, 2023 Rickisaft   153.74 Jan 09, 2023 @ 154.60 +0.56%
Nov 01, 2022 job job   145.21 Nov 28, 2022 @ 153.00 +5.36%
Oct 31, 2022 Paolo Causarano   143.66 Nov 28, 2022 @ 153.00 +6.50%
Oct 28, 2022 高 杉本   143.63 Nov 01, 2022 @ 145.61 +1.38%
Oct 21, 2022 Andrea Covello   134.64 Nov 11, 2022 @ 149.26 +10.86%
Sep 13, 2022 Josep Navarro   151.54 Oct 07, 2022 @ 135.80 -10.39%
Aug 31, 2022 Oriol Garcia   154.59 Sep 21, 2022 @ 134.99 +12.68%
Aug 16, 2022 Andrea Covello   161.22 Sep 09, 2022 @ 152.66 -5.31%
Aug 15, 2022 Allen Yong   158.98 Aug 22, 2022 @ 156.32 -1.67%
Aug 04, 2022 Jana Freimuth   152.46 Aug 26, 2022 @ 155.87 -2.24%
Aug 04, 2022 Allen Yong   152.12 Aug 08, 2022 @ 153.84 +1.13%
Jul 29, 2022 Dario Ermini   155.06 Aug 19, 2022 @ 156.55 +0.96%
Jul 28, 2022 Josep Navarro   156.48 Aug 19, 2022 @ 156.65 +0.11%
Jul 26, 2022 Jose Miguel Giráldez   158.39 Aug 19, 2022 @ 156.65 -1.10%
Jun 24, 2022 luca milioni   153.93 Jul 15, 2022 @ 157.44 +2.28%
Jun 13, 2022 Josep Navarro   143.10 Jul 08, 2022 @ 158.30 +10.62%
May 23, 2022 MadeForStreets   146.99 May 28, 2022 @ 150.91 +2.67%
More
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

JAZZ Comments

Write your thoughts about Jazz Pharmaceuticals PLC
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mar 01, 2023 5:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
avadel going to destroy number 1 products sales in less than 6 months.
Reply
0 0
Report
Mar 01, 2023 5:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
do the research you'll see for yourself
Reply
0 0
Report
AL Vla
AL Vla Jul 01, 2021 11:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
FDA Approves Component of Treatment Regimen for Most Common Childhood Cancerhttps://www.fda.gov/news-events/press-announcements/fda-approves-component-treatment-regimen-most-common-childhood-cancer
Reply
3 0
Report
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Reply
2 1
Report
Zoran Labus
Zoran Labus Mar 25, 2021 11:25AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
Reply
0 0
Report
Jesus Jerez
Jesus Jerez Feb 24, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Take into account the risks, page 44 of th eannual report: ""However, FDA confirmed that the clinical benefit of Zepzelca based on the results of the ATLANTIS Phase 3 clinical trial evaluating Zepzelca in combination with doxorubicin for relapsed SCLC did not provide sufficient verification and we and PharmaMar will therefore need to conduct one or more additional clinical trials of Zepzelca to confirm its clinical benefit. Our failure to do so could result in the withdrawal of approval of Zepzelca, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In any event, if we are unable to comply with our post-marketing obligations imposed as part of the marketing approvals in the U.S., the EU, or other European countries, our approval may be varied, suspended or revoked, product supply may be delayed and our sales of and revenues from our products could be materially adversely affected. ""
Reply
1 0
Report
Rober Asensio
Rober Asensio Feb 15, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
PharmaMar's antiviral is 100 times more effective against Covid-19 than other treatments, reducing its viral load by almost 100%
Reply
1 1
Report
Chema Gonzalvez
Chema Gonzalvez Oct 19, 2020 11:03AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
"The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
Reply
3 2
Report
Chema Gonzalvez
Chema Gonzalvez Oct 19, 2020 11:02AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
"The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
Reply
4 1
Report
Miosecops cook
Miosecops cook Oct 19, 2020 11:02AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
on so ii would need samples plenty and ill make my rounds
Reply
0 0
Report
Iscritto Iscritti
Iscritto Iscritti Aug 14, 2019 8:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I see it as a very good stock and see very good income statements but don't know the company.. any downsides about it ?
Reply
1 4
Report
Wojtek Stefanowicz
Wojtek Stefanowicz Feb 20, 2019 3:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buying now
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email